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Abstract
Background: Inhibition of the Na+/glucose co-transporter 2 
is a new therapeutic strategy for diabetes. It is unclear how 
proximal loss of Na+ (and glucose) affects the subsequent 
Na+ transporters in the proximal tubule (PT), thick ascending 
limb of loop of Henle (TAL), distal convoluted tubule (DCT) 
and collecting duct (CD). Methods: Mice on a high fat diet 
were administered 3 doses streptozotocin 6 days prior to 
oral dapagliflozin administration or vehicle for 18 days. A 
control group of lean mice were also included. Body weight 
and glucose were recorded at regular intervals during treat-
ment. Renal Na+ transporters expression in nephron seg-
ments were analyzed by RT-qPCR and Western blot. Results: 
Dapagliflozin treatment resulted in a significant reduction in 
body weight and blood glucose compared to vehicle-treat-
ed controls. mRNA results showed that Na+-hydrogen anti-
porter 3 (NHE3), Na+/phosphate cotransporter (NaPi-2a) and 
epithelial Na+ channel expression was increased, Ncx1, 
ENaCβ and ENaCγ expression declined (p all < 0.05), respec-
tively, in dapagliflozin-treated mice when compared with sa-
line vehicle mice. Na-K-2Cl cotransporters and Na-Cl cotrans-
porter mRNA expression was not affected by dapagliflozin 
treatment. Na+/K+-ATPase (Atp1b1) expression was also in-
creased significantly by dapagliflozin treatment, but it did 
not affect Atp1a1 and glucose transporter 2 expression. 
Western blot analysis showed that NaPi-2a, NHE3 and AT-
P1b1 expression was upregulated in dapagliflozin-treated 
diabetic mice when compared with saline vehicle mice (p < 
0.05). Conclusion: Our findings suggest that dapagliflozin 
treatment augments compensatory changes in the renal PT 
in diabetic mice. © 2019 The Author(s) 
Published by S. Karger AG, Basel
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Type 2 diabetes mellitus is a major health problem af-
fecting 415 million people worldwide [1, 2]. This repre-
sents 8.3% of the adult population, with equal rates in 
women and men [3]. From 2012 to 2015, approximately 
1.5–5.0 million deaths each year resulted from diabetes [4]. 
Diabetes and hypertension frequently occur together [5]. 
Hypertension in these patients further increases their al-
ready elevated cardiovascular risks, yet is difficult to man-
age. Indeed, in about half of the diabetic population, blood 
pressure targets are not met despite the use of multiple 
blood pressure lowering drugs, including diuretics [6–8].
Recently, dapagliflozin, a sodium-glucose co-trans-
porter 2 (SGLT2) inhibitor, was introduced as a novel 
class of glucose-lowering agents for the treatment of type 
2 diabetes. As SGLT2 is responsible for approximately 
90% of the filtered glucose reabsorption in the proximal 
tubule (PT) segment 1 and 2 [9–11], its inhibition reduc-
es renal glucose and sodium (Na+) reabsorption, leading 
to urinary glucose excretion and a reduction in blood glu-
cose levels [12]. Therefore, dapagliflozin is an efficient 
novel drug to treat patients with type 2 diabetes mellitus 
[13–16].
Some studies have also demonstrated that SGLT2 in-
hibitors exhibit an impressive diuretic effect and conse-
quent blood pressure reduction, whereas others de-
scribed modest effects on volume status [17–20]. SGLT2 
inhibition reduces PT Na+ reabsorption and thereby in-
creases the distal tubular Na+ load, which inhibits the 
renin-angiotensin-aldosterone system activation [21]. 
The kidneys efficiently reabsorb 99% of filtered Na+ by 
the combined action of (i) the PT where 60–70% is reab-
sorbed via Na+-hydrogen antiporter 3 (NHE3), SGLT1 
and SGLT2 [22]; (ii) the thick ascending limb (TAL) of 
Henle’s loop that is responsible for 15–25% reabsorption 
via paracellular routes and Na-K-2Cl cotransporter 
(NKCC2); (iii) the distal convoluted tubule (DCT) that 
reabsorbs 15–25% via the thiazide-sensitive Na-Cl co-
transporter (NCC) [23]; (iv) the collecting duct (CD) 
where the ENaC facilitates the reabsorption of the re-
maining 1–2% [10, 24]. 
A recent study has found that treatment with an 
SGLT2 inhibitor increases the expression of urea trans-
porter-A1, aquaporin-2 and NKCC2 proteins [1]. How-
ever, a systematic analysis of the compensatory mecha-
nisms that regulate renal Na+ reabsorption after SGLT2 
treatment is lacking. Knowledge of which nephron seg-
ment compensates for proximal Na+ loss is of great fun-
damental and clinical interest, as this would provide the 
major pharmacological target for antihypertensive treat-
ment.
The purpose of this study was to identify the compen-
satory impact of proximal Na+ wasting by the SGLT2 in-
hibitor, dapagliflozin, on renal Na+ transporters in high-
fat diabetic mice.
Materials and Methods
The Following Primary Antibodies Were Used
NCC (Millipore, Billerica, MA, USA; #AB3553; immunoblot-
ting [IB] 1: 2,000), and sheep anti NKCC2, IB 1: 2,000 [25], Na+/
phosphate cotransporter (NaPi-2a; kind gift of Dr. Custer et al. 
[26]; IB 1: 2,000), NHE3 (Millipore, Billerica, MA, USA; # AB3085; 
IB 1: 500) [27], ATP1b1 (Merck KGaA, Darmstadt, Germany; # 05-
382; IB 1: 500) [28]. Secondary antibodies were as follows: peroxi-
dase conjugated goat anti-rabbit (Sigma-Aldrich; # A4914; IB 1: 
10,000); peroxidase conjugated sheep anti-mouse (Jackson Immu-
noResearch Laboratories Inc., West Grove, PA, USA; #515-035-
003; IB 1: 10,000).
Buffers
Lysis buffer: 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 1 mM 
EDTA, 1 mM EGTA, 1 mM sodium-orthovanadate, 1% (v/v) Tri-
ton X-100, 10 mM sodium-glycerophosphate, 50 mM sodium fluo-
ride, 0.27 M sucrose, 10 mM sodium pyrophosphate, containing 
freshly added tablet of complete protease inhibitor cocktail (Roche, 
Basel, Switzerland) and 0.1% (v/v) β-mercaptoethanol. SDS-PAGE 
sample buffer: 5× 10% (w/v) SDS, 10 mM β-mercaptoethanol, 50% 
(v/v) glycerol, 0.3 M Tris-HCl (pH 7.5), 0.05% (w/v) bromophenol 
blue. TBS-T (Tris-buffered saline, 0.1% [v/v] Tween 20): Tris-HCl 
(200 mM, pH 7.5), 0.15 M NaCl, and 0.2% (v/v) Tween-20. 
Animal Model
Adult Swiss male mice (Harlan, Oxon, UK) at 16 weeks of age 
were housed in an air-conditioned room at 22 ± 2  ° C with 12: 12 h 
light/dark cycle. Mice had free access to high-fat diet (45% AFE 
Fat; Special Diet Services, Witham, UK; total energy 26.15 kJ/g). 
An additional lean group had free access to standard rodent chow 
(Teklad Global 18% Protein Rodent Diet; Harlan, UK; total energy 
13.0 kJ/g). All animals were free to access drinking water and re-
spective diet, and no adverse effects were observed during the en-
tire experimental study. All experiments were performed accord-
ing to the Principles of Laboratory Animal Care (NIH publication 
no. 86-23, revised 1985) and UK Home Office Regulations (UK 
Animals Scientific Procedures Act 1986). 
Experimental Treatments
Mice commenced high-fat diet on day –20 and remained on this 
diet for the duration of the study. On day –6, streptozotocin (50 mg/
kg; i.p.; Sigma-Aldrich, Dorset, UK) freshly prepared in ice-cold 0.1 
M Na+ citrate buffer (HCl/pH 4.5) was administered 3 doses in to-
tal over a period of 6 days to induce diabetes. On day 0, one group 
of high-fat mice (n = 8) commenced daily treatment with dapa-
gliflozin (1 mg/kg; p.o.; Stratech Scientific Ltd., Suffolk, UK) for 
18 days, whereas high-fat control group (n = 8) received saline ve-
hicle (0.9% w/v NaCl; p.o.) once-daily for the same time period. The 
volume for the oral gavage was 100 μL. A diagrammatic representa-
tion of the experimental design is shown in Figure 1.
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Quantitative Analyses of Gene Expression
At study termination, total RNA was extracted from mouse 
kidney tissues with Trizol (Invitrogen, Carlsbad, CA, USA) ac-
cording to the manufacturer’s protocol. Subsequently, mouse 
RNA samples were subjected to DNase treatment to prevent ge-
nomic DNA contamination and the reverse transcriptase reac-
tion was subsequently performed to synthesize cDNA [29]. 
mRNA levels of the target genes were determined by relative 
RT-qPCR following the MIQE guidelines 20 with a CFX96TM 
Real-Time PCR Detection System (Bio-Rad Laboratories, Her-
cules, CA, USA) using iQTM SYBR Green Supermix (Bio Rad) 
detection of single PCR product accumulation. Each group had 
8 kidneys and RT-qPCR experiments were commenced in trip-
licate. Primers for SGLT2, SGLT1, NHE3, NaPi-2a, NKCC2, 
NCC, Ncx1, ENaC (α, β, γ) were purchased from Biolegio BV 
(Nijmegen, Netherlands). In this study, gene expression levels 
were normalized to the expression levels of the standard species-
specific reference genes glyceraldehyde 3-phosphate dehydroge-
nase. Here, the relative mRNA expression was analyzed us-
ing the Livak method (2–ΔΔCt). Primer sequences are shown in 
Table 1. 
Protein Isolation
Kidney tissues were isolated from mice and homogenized in ice 
cold lysis buffer. The kidney lysates were clarified by  centrifugation 
at 4  ° C for 15 min at 16, 110 g and supernatants stored at –80  ° C. 
Bradford method was used to determine protein concentrations 
according to the manufacturer’s protocol (Bio-Rad).
Immunoblotting
Lysates (20 μg) in SDS sample buffer were added to electropho-
resis on Criterion TGX precast gels (Bio-Rad) and then the gels 
were transferred to PVDF membranes. The membranes were 
blocked in TBS-T containing 5% (w/v) non-fat dry milk (NFDM) 
for 1 h at room temperature. Subsequently, they were immunob-
lotted at 4  ° C with primary antibody overnight. Next day, the blots 
Lean
Group 1 18–20
Group 2
HFD STZ Saline
Commence treatments
18–20 –6 0
Group 3
HFD STZ DAPA
Commence treatments
18–20 –6 0
Table 1. Primer sequences used for real-time quantitative RT-PCR
Gene Forward primer 5′–3′ Reverse primer 5′–3′
SGLT2 ATGGAGCAACACGTAGAGGC ACATAGACCACAAGCCAACACC
SGLT1 TCTGTAGTGGCAAGGGGAAG ACAGGGCTTCTGTGTCTTGG
NaPi-2a AGGTGAGCTCCGCCATTCCGA CCCTGCAAAAGCCCGCCTGA
NKCC2 GGCTTGATCTTTGCTTTTGC CCATCATTGAATCGCTCTCC
NCC CTTCGGCCACTGGCATTCTG GATGGCAAGGTAGGAGATGG
Ncx1 TCCCTACAAAACTATTGAAGGCACA TTTCTCATACTCCTCGTCATCGATT
ENaCα GCTCAACCTTGACCTAGACCT GCGGTGGAACTCGATCAGT
ENaCβ GTCATCGGAACTTCACGCCTAT TCCTCCTGACCGATGTCCAG
ENaCγ TGACCTGCTTCTTCGATGGG TTGCAGACCATACTCACTGCC
Atp1a1 GGGGTTGGACGAGACAAGTAT CGGCTCAAATCTGTTCCGTAT
Atp1b1 ATCTCCTTCCGTCCTAATGACC CTCGAAAATCATGTCGTCCTTCT
Glut2 AGAAGACAAGATCACCGGAACC TCACACCGATGTCATAGCCG
GAPDH TAACATCAAATGGGGTGAGG GGTTCACACCCATCACAAAC
SGLT2, sodium-glucose co-transporter 2; NaPi-2a, Na+/phosphate cotransporter; NKCC2, Na-K-2Cl co-
transporter; NCC, Na-Cl cotransporter; ENaCα, epithelial Na+ channel; Glut2, glucose transporter 2; GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase.
Fig. 1. Timeline for the experimental study. 
Group 1 (lean control): lean mice on nor-
mal diet for 38 days. Group 2 (high-fat con-
trols): mice commenced a high fat diet on 
day –20 and subsequently received STZ 
treatment on day –6. At day 0, saline vehi-
cle was administered for 18 days. Group 3 
(high-fat dapagliflozin): mice commenced 
high fat diet on day –20 and subsequently 
received STZ on day –6. At day 0, dapa-
gliflozin was administered for 18 days. 
Lean, lean control mice; HFD, high fat diet 
treatment; DAPA, dapagliflozin-treated 
mice; STZ, streptozotocin-treated mice.
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were washed with TBS-T to remove unbound primary antibody 
and incubated with horseradish peroxidase conjugated secondary 
antibodies for 1 h at room temperature. After subsequent washes, 
the protein was visualized with chemiluminescent reagent (Super-
Signal West femto/pico; Thermo Scientific, Waltham, MA, USA) 
and processed with the Bio-Rad ChemiDoc XRS. The NaPi-2a, 
NaPi-2c, NHE3, NCC, NKCC2 and ATP1b1 bands on the immu-
noblots were quantified with gel analyzer.
Statistical Analyses
Data is shown as means ± SEM. One-way ANOVA followed by 
Scheffe’s test was used to examine the differences between groups. 
A p value < 0.05 was considered statistically significant. 
Results
Effects of High-Fat Feeding and Dapagliflozin on Body 
Weight and Blood Glucose
Mice receiving the high-fat diet increased in body 
weight from day –20 to day 0 more than those receiving 
normal chow (p < 0.05). From day 0 to 18, high-fat  control 
mice displayed a further modest increase in body weight 
(p < 0.05), whereas mice treated with dapagliflozin exhib-
ited a significant reduction in body weight (p < 0.05). 
Body weights of lean mice did not differ during the study. 
High-fat control mice displayed increased blood glucose 
concentrations from day 0 to 18 (p < 0.05). In contrast, 
high-fat mice treated with dapagliflozin exhibited a 
marked reduction in blood glucose (p < 0.05). Glucose 
concentrations were unchanged in lean mice. Results are 
shown in Table 2.
The Effect of Dapagliflozin on Na+ Transporter 
Expression in the PT
RT-qPCR was performed to analyze the renal ex-
pression of SGLT1, SGLT2, NHE3, NaPi-2a in the 
dapagliflozin-treated and control group mice. NHE3 
and NaPi-2a gene expression was increased significant-
ly by 33 and 34% (p < 0.05 each), respectively, in the 
dapagliflozin-treated mice compared to high-fat con-
trol group (Fig. 2c, d). In contrast, there were no sig-
nificant differences in the expression of SGLT2 and 
SGLT1 (p > 0.2) between the dapagliflozin-treated 
group and the vehicle-control group (Fig. 2a, b). Pro-
tein expression level of NaPi-2a and NHE3 was further 
investigated by Western blot analysis (Fig.  2e). The 
 expression of NaPi-2a and NHE3 was increased by 55 
and 139% in the dapagliflozin-treatment group when 
compared with saline vehicle diabetic mice (p < 0.05; 
Fig. 2f, g).
The Effect of Dapagliflozin on Na+ Transporter 
Expression in TAL and DCT
In order to study the effect of dapagliflozin on the ex-
pression of the Na+ transporters in the TAL and DCT, 
the expression of NKCC2, NCC and Ncx1 was analyzed 
by RT-qPCR. The expression of NKCC2 and NCC tend-
ed to increase by 23 and 17%, respectively, in the dapa-
gliflozin treatment group (Fig.  3a, b). However, these 
changes did not reach statistical significance. The ex-
pression of Ncx1 decreased by 27% in the dapagliflozin 
treatment group when compared with that of the vehi-
cle-control group (p < 0.05; Fig. 3c). Dapagliflozin treat-
ment did not alter NCC and NKCC2 protein abundance 
when compared with saline vehicle diabetic mice 
(Fig. 3e, f).
The Effect of Dapagliflozin on Na+ Transporter/
Channel Expression in the CD
To further investigate the effect of proximal Na+ loss 
on the CD, we tested the expression of the ENaC (α, β and 
γ) by RT-qPCR. Dapagliflozin treatment increased the 
expression of epithelial Na+ channel (ENaCα) by 29% 
Table 2. Effects of high fat feeding and dapagliflozin on body weight and blood glucose
Parameter Lean (n = 8) HF + saline (n = 8) HF + DAPA (n = 8)
0 day 18 days 0 day 18 days 0 day 18 days
Body weight, g 37.6±5.2 36±2.3 45.7±4.2 50.2±4.3a 43.5±5.7 37.6±5.2b
Blood glucose, mM 5.2±0.9 5.8±0.4 18.5±3.7 22.3±4.1a 17.6±1.7 7.6±2.1b
Data is mean ± SEM.
a p < 0.05 vs. lean.
b p < 0.05 vs. HF + saline.
Lean, lean control mice; HF + saline, saline vehicle diabetic mice; DAPA, dapagliflozin (1 mg/kg) treated diabetic mice. 0 day, day 0, 
saline vehicle and DAPA were administered; 18 days, day 18, saline vehicle and DAPA were administered for 18 days. 
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when compared with vehicle-control mice (p < 0.05) 
(Fig.  4a). In addition, the expression of ENaCβ and 
ENaCγ declined significantly by 13 and 26%, respectively, 
in the dapagliflozin-treated group compared to vehicle-
controls (p < 0.05 each; Fig. 4b, c). 
The Effect of Dapagliflozin on Expression of 
Na+-K+-ATPase and Glucose Transporters
We also evaluated the effect of dapagliflozin on glu-
cose transporter 2 (Glut2) and Na+-K+-ATPase trans-
porters by RT-qPCR. The expression of Atp1b1 was sig-
nificantly increased by 32% in the dapagliflozin-treated 
mice compared to that of the vehicle- control group (p < 
0.05; Fig. 5b). The expression of Atp1a1 was not changed 
in the dapagliflozin-treated group (p > 0.2). Dapa-
gliflozin treatment caused a slight reduction in the ex-
pression of Glut2 compared to the vehicle-control 
group, but this effect failed to reach statistical signifi-
cance (p = 0.08; Fig. 5a, c). Western blot analysis was 
further used to investigate the protein expression level 
of ATP1b1 (Fig. 5d). ATP1b1 expression was increased 
by 123% in the dapagliflozin-treatment group when 
compared with saline vehicle diabetic mice (p < 0.05; 
Fig. 5e).
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β-ActinFig. 2. Effect of dapagliflozin on the expres-
sion of the sodium transporters in the PT. 
a–d Quantitative RT-PCR analyses for the 
expression of SGLT2, SGLT1, NHE3 and 
NaPi-2a in the PT. e, f Immunoblot analy-
sis of NaPi-2a (∼70 kDa), NHE3 (∼93 kDa) 
in mice fed the indicated diet. g, h Histo-
grams for NaPi-2a, NHE3 Western blot re-
sults and normalized for β-actin expres-
sion. *  p < 0.05. Lean, lean control mice; 
HF, saline vehicle mice; DAPA, dapa-
gliflozin-treated mice. NHE3, Na+-hydro-
gen antiporter 3; NaPi-2a, Na+/phosphate 
cotransporter.
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Discussion
In this study, we demonstrated that the inhibition of 
SGLT2 increased the mRNA expression level of NHE3, 
NaPi-2a and ENaCα. Western blotting results show that 
the protein expression level of NHE3 and NaPi-2a was 
increased in dapagliflozin-treated mice. Moreover, AT-
P1b1 protein expression level was also increased. Our 
findings demonstrate that proximal inhibition of Na+ re-
absorption via SGLT2 is compensated by an increased ex-
pression of local Na+ transporters in the PT but not in the 
TAL, DCT and CD.
The kidneys reabsorb large amounts of filtered glucose 
to clear urinary glucose, primarily through the Na+-de-
pendent glucose co-transporter 2 (SGLT2) in the S1 seg-
ment of the PT. Inhibitors of SGLT2 are newly developed 
anti-diabetic agents and interfere with the pathway of 
physiological glucose reabsorption in the kidney. In this 
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study, high fat and STZ induction significantly increased 
blood glucose when compared with lean group mice. In 
the dapagliflozin treatment group, we found that blood 
glucose level decreased significantly when compared with 
that of the vehicle-control group. In our study, STZ-in-
duced diabetes decreased the SGLT2 expression. Alber-
toni Borghese et al. [30] have also demonstrated that STZ 
decreased the SGLT2 expression and activity. In contrast, 
the SGLT2 expression was increased in Akita/+ mice [31], 
humans [32] with type 2 diabetes, and alloxan-induced 
diabetic rats [33]. Indeed, the use of different diabetic 
models may, therefore, result in different SGLT2 expres-
sion. However, despite lower SGLT2 expression in STZ-
induced mice, dapagliflozin treatment reduced blood 
glucose levels. We therefore expect that in other studies 
with higher SGLT2 expression, the observed effects may 
even be larger. Moreover, dapagliflozin treatment did not 
change SGLT2 expression in our experiment. The expres-
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sion of SGLT2 does not necessarily alter upon dapa-
gliflozin treatment. Other studies also found that phar-
macological SGLT2 inhibition does not affect the expres-
sion of SGLT2 [31, 34]. Given the reduction of blood 
glucose concentrations in the dapagliflozin-treated group 
at day 18 when compared with saline vehicle mice, the 
lowered SGLT2 expression did not impair the effects of 
dapagliflozin treatment. Therefore, we do not expect that 
this has a major impact on our results. 
SGLT2 inhibitors improve glucose control by induc-
ing glycosuria, but they also reduce the reabsorption of 
Na+. Inhibition of Na+ reabsorption in the PT will switch 
on compensatory systems in more distally located seg-
ments to counteract the proximal Na+ loss. A recent study 
has shown that dapagliflozin treatment upregulated the 
expression of urea transporter-A1, aquaporin-2, and 
NKCC2 proteins [1]. However, little is known about the 
effects of SGLT2 inhibitors on the local and downstream 
Na+ transporters. We investigated how proximal Na+ 
wasting affects local and downstream Na+ transporters/
channels’ expression in high-fat diabetic mice.
The management of hypertension in diabetes is not 
without controversy [17]. Hence, the precise level at 
which anti-hypertensive therapy should be initiated and 
what the target blood pressure should be remain difficult 
issues. Many patients with type 2 diabetes receive multi-
ple drugs to treat both hyperglycaemia and hypertension. 
The new class of SGLT2 inhibitors also induces renal Na+ 
wasting and, therefore, will have blood pressure-reducing 
properties. However, some studies report an impressive 
diuretic effect and consequent reduction in blood pres-
sure, while others described modest effects on volume 
status [17, 35]. It is known that the compensatory capac-
ity of the kidney is immense [36]. The inhibition of Na+ 
reabsorption in the PT will turn on compensatory sys-
tems in local or more distally located segments to coun-
teract the proximal Na+ loss. 
In this study, dapagliflozin treatment significantly in-
creased the mRNA expression level of NHE3, NaPi-2a 
and ENaCα. In line with the mRNA expression level, 
Western blot results showed that NHE3, NaPi-2a also in-
creased in the dapagliflozin treatment group when com-
pared to that in saline vehicle mice. Therefore, our results 
suggest that the inhibition of Na+-glucose transporter 2 
in the PT can turn on the local and downstream Na+ com-
pensatory systems. Increased reabsorption of Na+ may el-
evate blood pressure in the type 2 diabetes [37–39]. Wang 
et al. [38] showed that a changed expression of Na+ trans-
port in renal PT can be compensated by changes in more 
distal tubule in nephron, tubuloglomerular feedback and 
also by glomerular filtration rate adjustments. Neverthe-
less, extracellular fluid volume and consequently blood 
pressure can also be affected by the changed expression 
of sodium transport in PT. Sodium reabsorption initially 
happens at the PT apical membrane, therefore resulting 
in making apical sodium transport critical in adjusting 
the extracellular fluid volume and ultimately blood pres-
sure control. Indeed, in polygenic human essential hyper-
tension, the increase in sodium transport occurs at the PT 
and TAL of Henle [40–42] rather than in more distal 
nephron segments that is characteristic of monogenic hy-
pertension [43]. Unfortunately, there were no plasma and 
urine electrolytes results in this study. Therefore, further 
studies are needed to better understand of the compensa-
tory mechanisms of Na+ transporters distal from the PT 
to adjust blood pressure control. 
SGLT2 is located in the S1 segment and accounts for 
90% of the glucose reabsorption from the kidneys [44–
47]. Na+ absorption across the cell membrane creates an 
energy gradient that in turn allows the absorption of glu-
cose. On the other side of the cell, Na+ is extruded through 
Na+-K+-ATPase into the bloodstream [48–50]. The con-
centration gradient within the cell, resulting from this ex-
change drives glucose reabsorption into the bloodstream 
via GLUT2 [51–53]. In order to evaluate if the increased 
expression of Na+ transporters in the PT and CD influ-
enced the expression of Na+-K+-ATPase and GLUT2, we 
furthermore tested the expression of Atp1a1 and Atp1b1 
and Glut2 transporters by RT-qPCR. The results revealed 
that the expression of Atp1b1 increased significantly in 
the dapagliflozin-treated group; however, the expression 
of Atp1a1 and Glut2 did not change. Furthermore, 
 ATP1b1 protein expression level was also increased in the 
dapagliflozin-treated group. The increased expression of 
ATP1b1 may facilitate Na+ to be transported into the 
bloodstream, which could lead to salt retention and hy-
pertension. These effects may blunt the potential BP-low-
ering effects of the SGLT2 inhibitor. This is also a risk for 
the type 2 diabetes patients to have hypertension [54]. 
In conclusion, we demonstrated that the SGLT2 in-
hibitor, dapagliflozin, increased the expression of NHE3, 
NaPi-2a in the PT. Furthermore, ATP1b1 was also up-
regulated, which may facilitate the uptake of the Na+ into 
the blood. 
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